GlassScriptPhysician profile
Angela Doan
NPI 1366991853
$5,583.07
in general payments reported to CMS, 2019-2025
34 companies · $2,538 in 2025
The $2,538 reported for 2025 was more than what 94% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $961 · 2022: $251 · 2023: $244 · 2024: $1,588 · 2025: $2,538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,214 · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,213.76 |
| Education | $157.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,000.30 | 2022-2025 | Breztri, Fasenra, Airsupra |
| Biohaven Pharmaceuticals, INC. | $892.10 | 2021 | |
| Genzyme Corporation | $500.38 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $453.12 | 2024-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $422.60 | 2024-2025 | Ofev, Jascayd |
| Baxter Healthcare | $238.03 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Glaxosmithkline, LLC. | $233.68 | 2023-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Abbvie INC. | $206.81 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $157.43 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $154.92 | 2025 | Winrevair, Zerbaxa |
| Pulmonx Corporation | $149.75 | 2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Abbott Laboratories | $129.61 | 2021-2024 | Freestyle Libre 2, Proclaim |
| Intuitive Surgical, INC. | $125.77 | 2025 | |
| Mylan Specialty L.P. | $111.90 | 2024 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $108.43 | 2022-2023 | Ajovy, Austedo, Austedo Xr |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $99.35 | 2025 | Ohtuvayre |
| United Therapeutics Corporation | $79.99 | 2025 | Tyvaso |
| Amgen INC. | $75.90 | 2024-2025 | Tezspire |
| Csl Behring | $59.49 | 2025 | Hizentra |
| Novo Nordisk INC | $52.15 | 2024-2025 | Ozempic, Rybelsus |
| Boston Scientific Corporation | $40.61 | 2021-2023 | |
| Grifols USA, LLC | $35.90 | 2025 | Xembify |
| Actelion Pharmaceuticals US, INC. | $27.78 | 2025 | Opsumit |
| Vifor Pharma, INC. | $27.20 | 2024 | Zemaira |
| Genentech USA, INC. | $27.11 | 2025 | Xolair |
| Insmed, INC. | $25.45 | 2025 | Arikayce |
| Viatris Specialty LLC | $25.40 | 2025 | Yupelri |
| Pharming Healthcare, INC. | $24.09 | 2025 | Ruconest |
| Zoll Respicardia, INC. | $23.52 | 2024 | Remede System |
| Inspire Medical Systems, INC. | $23.18 | 2024 | Inspire |
| Philips North America LLC | $14.60 | 2024 | (8874) Incourage |
| Phadia US INC. | $12.74 | 2023 | Immunocap |
| Lilly USA, LLC | $12.39 | 2022 | |
| 3b Medical, INC. | $11.39 | 2025 | Luna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Doan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.